Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms MAD study
- Sponsors PegBio
- 13 Jun 2017 Results (n=76) assessing effect of race on tolerability, safety, PK/PD of exenatide using patient data from NCT03059719 and NCT03072407 trials, presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 09 Mar 2017 New trial record